The General Hospital Corporation (MGH), through its Research Management Division, has been awarded a $485,558 Project Grant (R01CA279173) by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The 5-year grant is focused on characterizing a novel glutathione-dependent metabolic pathway that drives metastatic growth in pancreatic ductal adenocarcinoma (PDA), a leading cause of cancer-related death. The research aims to molecularly define the key factors in this pathway, GSTT1 and SLC38A4, and understand how their expression and repurposed function in metastatic cells enables extracellular matrix remodeling and expansion of metastatic lesions. By taking advantage of biochemistry, cell biology, genetically-engineered mouse models, and human patient samples, the project seeks to provide fundamental insights that could lead to new diagnostic markers and therapeutic strategies for treating metastatic PDA, an area of significant unmet need.
Generated 2/25/25, 5:15 AM